Morgan Stanley
NAGE

Morgan Stanley’s Niagen Bioscience NAGE Stock Holding History

Morgan Stanley’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Sell
381,089
-499,035
-57% -$2.69M ﹤0.01% 4871
2025
Q4 		$5.6M Buy
880,124
+351,753
+67% +$2.45M ﹤0.01% 4093
2025
Q3 		$4.93M Sell
528,371
-78,347
-13% -$791K ﹤0.01% 4163
2025
Q2 		$8.74M Buy
606,718
+341,773
+129% +$3.37M ﹤0.01% 3559
2025
Q1 		$1.83M Buy
264,945
+110,071
+71% +$692K ﹤0.01% 4663
2024
Q4 		$822K Sell
154,874
-8,753
-5% -$47.9K ﹤0.01% 5188
2024
Q3 		$597K Buy
163,627
+93,880
+135% +$295K ﹤0.01% 5317
2024
Q2 		$190K Buy
69,747
+24,991
+56% +$83.6K ﹤0.01% 5704
2024
Q1 		$156K Buy
44,756
+31,778
+245% +$58.8K ﹤0.01% 5814
2023
Q4 		$18.6K Buy
12,978
+6,776
+109% +$9.44K ﹤0.01% 6689
2023
Q3 		$9.05K Sell
6,202
-2,271
-27% -$3.55K ﹤0.01% 6763
2023
Q2 		$13.3K Sell
8,473
-1,556
-16% -$2.32K ﹤0.01% 6704
2023
Q1 		$15.3K Sell
10,029
-4,667
-32% -$8.31K ﹤0.01% 6728
2022
Q4 		$24.7K Sell
14,696
-10,715
-42% -$17K ﹤0.01% 6594
2022
Q3 		$31K Sell
25,411
-129,871
-84% -$209K ﹤0.01% 6613
2022
Q2 		$259K Buy
155,282
+72,601
+88% +$142K ﹤0.01% 5767
2022
Q1 		$203K Sell
82,681
-2,655
-3% -$7.25K ﹤0.01% 5921
2021
Q4 		$319K Sell
85,336
-14,468
-14% -$78.1K ﹤0.01% 5809
2021
Q3 		$626K Sell
99,804
-48,084
-33% -$396K ﹤0.01% 5352
2021
Q2 		$1.46M Sell
147,888
-215,756
-59% -$1.88M ﹤0.01% 4863
2021
Q1 		$3.4M Sell
363,644
-358,581
-50% -$2.84M ﹤0.01% 3810
2020
Q4 		$3.47M Buy
722,225
+84,167
+13% +$410K ﹤0.01% 3660
2020
Q3 		$2.56M Buy
638,058
+171,900
+37% +$829K ﹤0.01% 3438
2020
Q2 		$2.14M Buy
466,158
+453,136
+3,480% +$2.03M ﹤0.01% 3525
2020
Q1 		$42K Sell
13,022
-51,875
-80% -$199K ﹤0.01% 5535
2019
Q4 		$279K Buy
64,897
+43,643
+205% +$155K ﹤0.01% 5259
2019
Q3 		$84K Buy
21,254
+10,530
+98% +$44.9K ﹤0.01% 5508
2019
Q2 		$50K Sell
10,724
-52,557
-83% -$224K ﹤0.01% 5610
2019
Q1 		$265K Sell
63,281
-24,162
-28% -$87.1K ﹤0.01% 4912
2018
Q4 		$300K Buy
87,443
+3,148
+4% +$10.9K ﹤0.01% 5097
2018
Q3 		$362K Sell
84,295
-22,211
-21% -$95.5K ﹤0.01% 5166
2018
Q2 		$395K Sell
106,506
-8,918
-8% -$33.9K ﹤0.01% 5242
2018
Q1 		$484K Buy
115,424
+99,124
+608% +$519K ﹤0.01% 5021
2017
Q4 		$96K Buy
16,300
+14,200
+676% +$76.7K ﹤0.01% 5643
2017
Q3 		$9K Buy
2,100
+596
+40% +$2.18K ﹤0.01% 6196
2017
Q2 		$6K Sell
1,504
-36,186
-96% -$115K ﹤0.01% 6329
2017
Q1 		$101K Sell
37,690
-45,620
-55% -$129K ﹤0.01% 5598
2016
Q4 		$276K Buy
83,310
+78,077
+1,492% +$212K ﹤0.01% 5218
2016
Q3 		$16K Buy
5,233
+653
+14% +$2.4K ﹤0.01% 5983
2016
Q2 		$19K Buy
+4,580
New +$21.7K ﹤0.01% 5870

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley's NAGE Position: Q1 2026 in Review

Morgan Stanley reduced its Niagen Bioscience (NAGE) stake by 57% in Q1 2026, selling an estimated $2.69M and leaving 381,089 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #4871.

Morgan Stanley first reported a position in NAGE in Q2 2016 and has held it in 40 quarters since. The position peaked at $8.74M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Morgan Stanley held 381,089 shares of Niagen Bioscience worth $1.68M as of Q1 2026.
  • Morgan Stanley sold 499,035 Niagen Bioscience shares in Q1 2026, an estimated $2.69M.
  • Niagen Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4871 holding.
  • Morgan Stanley first reported a position in Niagen Bioscience in Q2 2016 and has held it in 40 quarters since.
  • Morgan Stanley's Niagen Bioscience position peaked at $8.74M in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.